Biotech Investing: Understanding Senolytic Drugs

In honor of Halloween, one of my absolute favorite holidays, I felt it was fitting to write about zombie cells a.k.a. “senescent” cells, and one of the companies trying to defeat them. Senescent cells no longer divide and accumulate with age, causing tissue damage within the body. They are pretty much living dead activly wreaking health havoc. In my last post detailing my attempt at making myself believe in buy and hold investing, I mentioned a company I’ve been following called Unity Biotechnology (NASDAQ: UBX). Unity is one of the many biotech companies driving the scientific movement of treating biological aging as a disease. They are developing senolytic treatments, types of drugs that

Attempting to Believe in Buy and Hold Investing

I tried to write a serious post on my recent experience of actively attempting to make myself believe in buy and hold investing, but realized I am a ridiculous person, so it’s only semi-serious as it’s an actual play-by-play of my thought processes. Since this ended up turning into a few chapters of my weird future autobiography, I took the opportunity to weave in some basic investment concepts and present them forth in a (hopefully) not dry and boring way. I did this because whenever I ask my non-investing friends why they aren’t into it, they usually say it’s because a lot of the info out there is boring. What do I mean by buy and hold? Different people have different definitions of what b

Genome Editing: A New Breed of Genetic Engineering

On Wednesday, the FDA finally lifted their hold on CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals' (NASDAQ:VRTX) CRISPR-Cas9 US clinical trial for their drug CTX001. The treatment aims to implement gene editing to treat sickle cell disease and if the trial does commence by end of the year as scheduled, it will be the first ever US CRISPR-Cas9 clinical trial. CRISPR and Vertex had previously obtained approvals for clinical trials to use CTX001 for both sickle cell disease and another blood disorder, Beta thalassemia, in countries outside the US. Though this news is prolific for the scientific community and the advancement of using genome editing technology to treat disease, it d